VV-scFv-TIGIT

VV-scFv-TIGIT is an engineered oncolytic vaccinia virus (VV) designed for cancer immunotherapy. It is genetically modified to encode and secrete a functional single-chain variable fragment (scFv) targeting the immune checkpoint T-cell immunoglobulin and ITIM domain (TIGIT). Developed by researchers at Nanjing University and Inner Mongolia Medical University, VV-scFv-TIGIT selectively replicates within and lyses tumor cells, while simultaneously delivering the anti-TIGIT scFv directly into the tumor microenvironment. This dual mechanism of action promotes tumor cell lysis and blocks the TIGIT pathway, thereby enhancing CD8+ T-cell infiltration and activation, and reversing local immunosuppression. In preclinical models, VV-scFv-TIGIT has demonstrated potent antitumor efficacy, particularly when combined with other immune checkpoint inhibitors such as PD-1 or LAG-3 blockades.

Other names

TIGIT-targeting scFv-armed vaccinia virusengineered VV-scFv-TIGIT